Understanding the role of Arsenic in modulating PML/TRIM19 activity

Arsenic is used therapeutically to treat Acute Promyelocytic Leukaemia by inducing SUMO- dependent, ubiquitin-mediated degradation of the PML- RAR oncoprotein. The objective of the work will be to define the mechanism by which arsenic induces SUMO modification of PML (TRIM19) and will involve a combination of biochemical, proteomic and structural biology approaches.